Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients began
On Apr. 22, 2021, the NIH announced that a phase 3 trial to test the safety and efficacy…
-
-
The WHO announced continued review of emerging evidence on AstraZeneca COVID-19 vaccines
On Apr. 22, 2021, the Strategic Advisory Group of Experts (SAGE) on Immunization annouced updated interim guidance on…
-
Quidel signed retail distribution agreement to increase access to at-home COVID-19 testing
On Apr. 22, 2021, Quidel announced that it had completed a distribution and fulfillment agreement with McKesson to…
-
FDA completed inspection of Emergent BioSolutions vaccine production facility
On Apr. 21, 2021, the FDA announced that it had completed an inspection of the Emergent BioSolutions and…
-
XPhyto signed German distribution, storage and logistics agreement for 25-minute COVID-19 PCR test
On Apr. 21, 2021, XPhyto announced that it had entered into an agreement with an established German pharmaceutical…
-
Valneva initiated pivotal phase 3 clinical trial for inactivated, COVID-19 vaccine using Dynavax’s CpG 1018ﾙ adjuvant
On Apr. 21, 2021, Dynavax Technologies announced Valneva had initiated a pivotal Phase 3 clinical trial for its…
-
Trevena announced TRV027 selected for study in global REMAP-CAP trial in COVID-19 patients
On Apr. 21, 2021,Trevena announced that TRV027, the Companyﾒs novel AT1 receptor selective agonist, had been selected for…
-
Large NIH clinical trial tested polyclonal antibody therapeutic for COVID-19
On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal…
-
Johnson & Johnson COVID-19 vaccine roll-out resumed in Europe following EMA review
On Apr. 20, 2021, Johnson & Johnson announced that the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee had…
-
Oxford University and Prenetics announced landmark collaboration to scale rapid testing tech globally
On Apr. 20, 2021, the University of Oxford, Prenetics, and Oxford Suzhou Centre for Advanced Research announced that…
-
Labcorp launched COVID-19 test kits for small businesses to support return to work safely
On Apr. 20, 2021, LabCorp announced the availability of the Pixel by Labcorpﾮ COVID-19 PCR Test Home Collection…
-
Pfizer and BioNTech supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
-
Abbott began shipping BinaxNOWﾙ COVID-19 Ag self test to retailers
On Apr. 19, 2021, Abbott announced it had begun shipping its BinaxNOWﾙ COVID-19 Ag Self Test to retailers…
-
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
-
Large clinical trial launched to study repurposed drugs to treat COVID-19 symptoms
On Apr. 19, 2021, the NIH announced that it was funding a large, randomized, placebo-controlled Phase 3 clinical…
-
Biotechnology | COVID-19 | Diagnostics | Genomics | Infectious Disease | Non-Profit Research | Therapeutics
Texas A&M lab identified new COVID-19 variant; genome suggested potential resistance to antibodies
On Apr. 19, 2021, scientists at the Texas A&M University Global Health Research Complex (GHRC) announced they had…
-
FDA revoked Emergency Use Authorization for monoclonal antibody bamlanivimab
On Apr. 16, 2021, the FDA revoked the emergency use authorization (EUA) that allowed for Eli Lilly’s investigational…
-
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
-
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
-
IH closed enrollment in trial comparing COVID-19 treatment regimens
On Apr. 15, 2021, The National Institute of Allergy and Infectious Diseases (NIAID) announced that the fourth iteration…
-
Experimental antiviral for COVID-19 was effective in hamster study
On Apr. 15, 2021, the National Institutes of Health announced that the experimental antiviral drug MK-4482 significantly decreased…
-
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
-
Biotechnology | Clinical Research | COVID-19 | FDA | HIV | Infectious Disease | Oncology | Therapeutics
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
-
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
-
AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
-
NIAID trial of Anti-CD14 antibody to treat COVID-19 respiratory disease began
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
-
Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
-
Moderna announced clinical progress from mRNA Vaccine
On Apr. 13, 2021, Moderna announced clinical and supply updates on its COVID-19 Vaccine program. New results from…
-
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
-
Phase III trial showed subcutaneous administration of investigational antibody cocktail reduced risk of symptomatic COVID-19 infections by 81%
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
